Healio

Alternative complement pathway inhibition may be key to lupus management

Please provide your email address to receive an email when new articles are posted on . Kim’s hypothesis arises partially from studies that showed that C3, when introduced to synthetic neutrophils, ...
Healio

‘Important discovery’ shows how complement cascade drives systemic inflammation

Please provide your email address to receive an email when new articles are posted on . A protein known as granzyme K was recently shown to be a driver of inflammation by activating the complement ...
Seeking Alpha

Dianthus Therapeutics: Complement System Candidate Not Sufficiently Derisked

Dianthus achieved its NASDAQ listing last year via a merger with Magenta Therapeutics. The company is focused on development of a single drug candidate, DNTH-103, which targets the complement system, ...
Pharm Exec

Jasper Therapeutics to Acquire Kira Pharmaceuticals in $132 Million Merger Agreement

Kp-104 (vensobafusp alfa) advances as a Phase II/III-ready bifunctional complement biologic targeting alternative and terminal pathways, with rare renal Phase II basket interim reads in Q4 2026 and Q2 ...
Monthly Prescribing Reference

Bifunctional Biologic Gets Orphan Drug Status for Paroxysmal Nocturnal Hemoglobinuria

Image of blood cells. KP104 is a bifunctional, first-in-class biologic that works by selectively inhibiting the alternative and terminal pathways in the complement system. The Food and Drug ...